By detecting the expression levels of ER and progesterone receptor (PgR), as well as the HER2 and Ki-67, BC were identified into categories with similar clinical implications, including Luminal A, Luminal B, HER2-positive, and triple-negative breast cancer (TNBC) subtypes [7]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.